This may be all the money Biolex needs to complete the rest of phase-2 and all of phase-3. If the FDA allows a 505b2 application, the cost (and time) of the clinical program will of course be reduced.
Democritus_of_Abdera, an assistant moderator on the SRDX board, has compiled a ReadMeFirst for the Dutch biotech company, OctoPlus (OCTO.AS), which has a relationship with SRDX. The RMF is at #msg-33431301. A button pointing to latest version of the RMF will be kept in the iBox of the Biotech Values board and the SRDX board.
I’ve followed OctoPlus cursorily for the past couple of years because of the Locteron program in HCV (#msg-33467893). Lately, the share price has taken a dive that strikes me as an overreaction based on fundamentals. (This is a familiar story these days for small, pre-commercial biotech companies.)
Feel free to comment on OctoPlus either here or on the SRDX board.
Market Data 
Markets 
AI
